Literature DB >> 17001036

Determination of the human type I interferon receptor binding site on human interferon-alpha2 by cross saturation and an NMR-based model of the complex.

Sabine R Quadt-Akabayov1, Jordan H Chill, Rina Levy, Naama Kessler, Jacob Anglister.   

Abstract

Type I interferons (IFNs) are a family of homologous helical cytokines that exhibit pleiotropic effects on a wide variety of cell types, including antiviral activity and antibacterial, antiprozoal, immunomodulatory, and cell growth regulatory functions. Consequently, IFNs are the human proteins most widely used in the treatment of several kinds of cancer, hepatitis C, and multiple sclerosis. All type I IFNs bind to a cell surface receptor consisting of two subunits, IFNAR1 and IFNAR2, associating upon binding of interferon. The structure of the extracellular domain of IFNAR2 (R2-EC) was solved recently. Here we study the complex and the binding interface of IFNalpha2 with R2-EC using multidimensional NMR techniques. NMR shows that IFNalpha2 does not undergo significant structural changes upon binding to its receptor, suggesting a lock-and-key mechanism for binding. Cross saturation experiments were used to determine the receptor binding site upon IFNalpha2. The NMR data and previously published mutagenesis data were used to derive a docking model of the complex with an RMSD of 1 Angstrom, and its well-defined orientation between IFNalpha2 and R2-EC and the structural quality greatly improve upon previously suggested models. The relative ligand-receptor orientation is believed to be important for interferon signaling and possibly one of the parameters that distinguish the different IFN I subtypes. This structural information provides important insight into interferon signaling processes and may allow improvement in the development of therapeutically used IFNs and IFN-like molecules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001036      PMCID: PMC2242419          DOI: 10.1110/ps.062283006

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  48 in total

Review 1.  Mapping protein-protein interactions in solution by NMR spectroscopy.

Authors:  Erik R P Zuiderweg
Journal:  Biochemistry       Date:  2002-01-08       Impact factor: 3.162

Review 2.  The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions.

Authors:  Jerome A Langer; E Cali Cutrone; Sergei Kotenko
Journal:  Cytokine Growth Factor Rev       Date:  2004-02       Impact factor: 7.638

3.  The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding.

Authors:  Jordan H Chill; Sabine R Quadt; Rina Levy; Gideon Schreiber; Jacob Anglister
Journal:  Structure       Date:  2003-07       Impact factor: 5.006

4.  Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.

Authors:  Peter Lamken; Suman Lata; Martynas Gavutis; Jacob Piehler
Journal:  J Mol Biol       Date:  2004-07-30       Impact factor: 5.469

5.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

6.  Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site.

Authors:  Laila C Roisman; Diego A Jaitin; Darren P Baker; Gideon Schreiber
Journal:  J Mol Biol       Date:  2005-10-21       Impact factor: 5.469

7.  Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography.

Authors:  R Radhakrishnan; L J Walter; A Hruza; P Reichert; P P Trotta; T L Nagabhushan; M R Walter
Journal:  Structure       Date:  1996-12-15       Impact factor: 5.006

8.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

Review 9.  Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

10.  Differences in activity between alpha and beta type I interferons explored by mutational analysis.

Authors:  L Runkel; L Pfeffer; M Lewerenz; D Monneron; C H Yang; A Murti; S Pellegrini; S Goelz; G Uzé; K Mogensen
Journal:  J Biol Chem       Date:  1998-04-03       Impact factor: 5.157

View more
  12 in total

1.  Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus.

Authors:  Songying Ouyang; Bin Gong; Jin-Zhi Li; Li-Xia Zhao; Wei Wu; Fu-Shun Zhang; Lina Sun; Shu-Jun Wang; Meng Pan; Chuan Li; Wenguang Liang; Neil Shaw; Jie Zheng; Guo-Ping Zhao; Ying Wang; Zhi-Jie Liu; Mifang Liang
Journal:  J Mol Med (Berl)       Date:  2012-02-04       Impact factor: 4.599

2.  The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling.

Authors:  Zongli Li; Jennifer Julia Strunk; Peter Lamken; Jacob Piehler; Thomas Walz
Journal:  J Mol Biol       Date:  2007-12-08       Impact factor: 5.469

3.  Observation of intermolecular interactions in large protein complexes by 2D-double difference nuclear Overhauser enhancement spectroscopy: application to the 44 kDa interferon-receptor complex.

Authors:  Ilona Nudelman; Sabine R Akabayov; Tali Scherf; Jacob Anglister
Journal:  J Am Chem Soc       Date:  2011-08-23       Impact factor: 15.419

Review 4.  IFNA2: The prototypic human alpha interferon.

Authors:  Franciane Paul; Sandra Pellegrini; Gilles Uzé
Journal:  Gene       Date:  2015-05-14       Impact factor: 3.688

5.  Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice.

Authors:  J Kärner; A Meager; M Laan; J Maslovskaja; M Pihlap; A Remm; E Juronen; A S B Wolff; E S Husebye; K T Podkrajšek; N Bratanic; T Battelino; N Willcox; P Peterson; K Kisand
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

6.  Enhancement of cell type specificity by quantitative modulation of a chimeric ligand.

Authors:  Pablo Cironi; Ian A Swinburne; Pamela A Silver
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

7.  NMR mapping of the IFNAR1-EC binding site on IFNalpha2 reveals allosteric changes in the IFNAR2-EC binding site.

Authors:  Sabine Ruth Akabayov; Zohar Biron; Peter Lamken; Jacob Piehler; Jacob Anglister
Journal:  Biochemistry       Date:  2010-02-02       Impact factor: 3.162

8.  Intermolecular interactions in a 44 kDa interferon-receptor complex detected by asymmetric reverse-protonation and two-dimensional NOESY.

Authors:  Ilona Nudelman; Sabine R Akabayov; Einat Schnur; Zohar Biron; Rina Levy; Yingqi Xu; Daiwen Yang; Jacob Anglister
Journal:  Biochemistry       Date:  2010-06-29       Impact factor: 3.162

9.  Structural linkage between ligand discrimination and receptor activation by type I interferons.

Authors:  Christoph Thomas; Ignacio Moraga; Doron Levin; Peter O Krutzik; Yulia Podoplelova; Angelica Trejo; Choongho Lee; Ganit Yarden; Susan E Vleck; Jeffrey S Glenn; Garry P Nolan; Jacob Piehler; Gideon Schreiber; K Christopher Garcia
Journal:  Cell       Date:  2011-08-19       Impact factor: 41.582

10.  Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab.

Authors:  Vaheh Oganesyan; Li Peng; Robert M Woods; Herren Wu; William F Dall'Acqua
Journal:  J Biol Chem       Date:  2015-04-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.